prednisone has been researched along with Febrile Neutropenia in 26 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Febrile Neutropenia: Fever accompanied by a significant reduction in the number of NEUTROPHILS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " S0806 was a single arm phase I/II trial of vorinostat given at 400 mg po daily on days 1-9 (subsequently amended to days 1-5 due to toxicity), combined with R-CHOP given on day 3 of a 21-day cycle for 8 cycles, with primary phase II endpoint of 2-year progression free survival (PFS)." | 6.87 | A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. ( Bane, CL; Barr, PM; Fisher, RI; Friedberg, JW; LeBlanc, M; Li, H; Persky, DO; Popplewell, LL; Rimsza, LM; Smith, SM; Von Gehr, A, 2018) |
| "Patterns of myeloid growth factor (GF) usage and febrile neutropenia (FN) were examined in patients >60 years of age with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) enrolled on CALGB 9793/ECOG-SWOG 4494, receiving initial therapy with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or rituximab + CHOP (R-CHOP)." | 5.24 | Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494). ( Cheson, BD; Fisher, RI; Habermann, TM; Li, S; Morrison, VA; Peterson, BA; Weller, EA, 2017) |
| "Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP)." | 4.12 | Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. ( Choi, YS; Do, YR; Eom, HS; Hyun, SY; Jeong, SH; Jo, JC; Kang, HJ; Kim, HJ; Kim, MK; Kim, SH; Kim, SJ; Kim, WS; Koh, Y; Kwak, JY; Kwon, JH; Lee, GW; Lee, HS; Lee, WS; Oh, SY; Park, BB; Park, Y; Shin, HJ; Sohn, BS; Suh, C; Won, JH; Yang, DH; Yi, JH; Yi, SY; Yoo, KH; Yoon, DH; Yun, HJ, 2022) |
| ", we analyzed 262 patients who had been treated with Ruximab-cyclophosphamide, doxorubicin, vincristine, and prednisone for newly diagnosed diffuse large B-cell lymphoma (DLBCL) and for whom data were available regarding pretreatment nutritional status." | 3.80 | Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. ( Cho, JW; Han, B; Kim, S; Kim, SJ; Kim, WS; Park, S; Woo, SY, 2014) |
| "An observational population-based cohort study was performed to investigate the role of comorbidity on outcome and treatment-related toxicity in patients with newly diagnosed advanced-stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)." | 3.80 | Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. ( Beerden, T; Boslooper, K; Hoogendoorn, M; Joosten, P; Kibbelaar, RE; Kluin-Nelemans, HC; Storm, H; van Kamp, H; van Rees, B; van Roon, EN; Veeger, NJ; Veldhuis, GJ; Wieringa, A, 2014) |
| "Ribociclib, a CDK4/6 inhibitor, demonstrates preclinical antitumor activity in combination with taxanes." | 3.11 | A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. ( Aggarwal, R; Carneiro, BA; de Kouchkovsky, I; Fong, L; Friedlander, T; Lewis, C; Paris, PL; Phone, A; Rao, A; Ryan, CJ; Small, EJ; Szmulewitz, RZ; Zhang, L, 2022) |
| " S0806 was a single arm phase I/II trial of vorinostat given at 400 mg po daily on days 1-9 (subsequently amended to days 1-5 due to toxicity), combined with R-CHOP given on day 3 of a 21-day cycle for 8 cycles, with primary phase II endpoint of 2-year progression free survival (PFS)." | 2.87 | A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. ( Bane, CL; Barr, PM; Fisher, RI; Friedberg, JW; LeBlanc, M; Li, H; Persky, DO; Popplewell, LL; Rimsza, LM; Smith, SM; Von Gehr, A, 2018) |
| " Efficacy assessment was based on incidence of FN and serious neutropenia (neutrophil count <500/μL), hospitalization days and chemotherapy dosage level." | 1.51 | [Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy]. ( Izumitani, S; Kataoka, T; Matsuo, H; Murase, T; Nishigakiuchi, R; Saeki, Y; Sakurashita, H; Taogoshi, T, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.85) | 29.6817 |
| 2010's | 16 (61.54) | 24.3611 |
| 2020's | 9 (34.62) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuda, K | 1 |
| Jo, T | 1 |
| Shimura, A | 1 |
| Honda, A | 1 |
| Taoka, K | 1 |
| Masamoto, Y | 1 |
| Matsui, H | 1 |
| Fushimi, K | 1 |
| Yasunaga, H | 1 |
| Kurokawa, M | 1 |
| Kim, DY | 1 |
| Nam, J | 1 |
| Chung, JS | 1 |
| Jeon, BE | 1 |
| Lee, JH | 1 |
| Jo, JC | 2 |
| Kim, SW | 1 |
| Shin, HJ | 3 |
| Jeong, SH | 1 |
| Kim, SJ | 3 |
| Yoon, DH | 2 |
| Park, Y | 2 |
| Kang, HJ | 2 |
| Koh, Y | 1 |
| Lee, GW | 1 |
| Lee, WS | 1 |
| Yang, DH | 1 |
| Do, YR | 1 |
| Kim, MK | 2 |
| Yoo, KH | 1 |
| Choi, YS | 1 |
| Yun, HJ | 1 |
| Yi, JH | 1 |
| Eom, HS | 2 |
| Kwak, JY | 1 |
| Park, BB | 1 |
| Hyun, SY | 1 |
| Yi, SY | 1 |
| Kwon, JH | 1 |
| Oh, SY | 1 |
| Kim, HJ | 1 |
| Sohn, BS | 1 |
| Won, JH | 1 |
| Kim, SH | 1 |
| Lee, HS | 2 |
| Suh, C | 2 |
| Kim, WS | 2 |
| de Kouchkovsky, I | 1 |
| Rao, A | 1 |
| Carneiro, BA | 1 |
| Zhang, L | 1 |
| Lewis, C | 1 |
| Phone, A | 1 |
| Small, EJ | 1 |
| Friedlander, T | 1 |
| Fong, L | 1 |
| Paris, PL | 1 |
| Ryan, CJ | 1 |
| Szmulewitz, RZ | 1 |
| Aggarwal, R | 1 |
| Kim, K | 1 |
| Lee, JJ | 1 |
| Kim, I | 1 |
| Kim, JS | 1 |
| Mun, YC | 1 |
| Lim, SN | 1 |
| Choi, CW | 2 |
| Yoon, SS | 1 |
| Min, CK | 1 |
| Kang, KW | 1 |
| Lee, BH | 1 |
| Jeon, MJ | 1 |
| Yu, ES | 1 |
| Kim, DS | 1 |
| Lee, SR | 1 |
| Sung, HJ | 1 |
| Kim, BS | 1 |
| de la Cruz-Benito, B | 1 |
| Lázaro-Del Campo, P | 1 |
| Ramírez-López, A | 1 |
| de Soto-Álvarez, T | 1 |
| Sánchez-Vadillo, I | 1 |
| García-Pérez, E | 1 |
| Dos Santos-Ortas, A | 1 |
| Humala-Barbier, K | 1 |
| López-de la Guía, A | 1 |
| Casado-Abad, G | 1 |
| Jiménez-Yuste, V | 1 |
| Canales-Albendea, M | 1 |
| Matsuda, S | 1 |
| Suzuki, R | 1 |
| Takahashi, T | 2 |
| Suehiro, Y | 1 |
| Tomita, N | 1 |
| Izutsu, K | 1 |
| Fukuhara, N | 1 |
| Imaizumi, Y | 1 |
| Shimada, K | 1 |
| Nakazato, T | 2 |
| Yoshida, I | 2 |
| Miyazaki, K | 1 |
| Yamaguchi, M | 1 |
| Suzumiya, J | 1 |
| Yokoyama, M | 2 |
| Kusano, Y | 2 |
| Inoue, N | 2 |
| Nishimura, N | 2 |
| Mishima, Y | 2 |
| Nukada, T | 2 |
| Hatake, K | 2 |
| Terui, Y | 2 |
| Arakaki, H | 1 |
| Osada, Y | 1 |
| Ito, C | 1 |
| Aisa, Y | 1 |
| Mori, T | 1 |
| Takahashi, A | 1 |
| Ueda, K | 1 |
| Nomura, T | 1 |
| Maeda, Y | 1 |
| Nishimori, H | 1 |
| Hiramatsu, Y | 1 |
| Uno, M | 1 |
| Masaki, Y | 1 |
| Sunami, K | 1 |
| Masunari, T | 1 |
| Nawa, Y | 1 |
| Yamane, H | 1 |
| Gomyo, H | 1 |
| Yano, T | 1 |
| Matsuo, K | 1 |
| Ohshima, K | 1 |
| Nakamura, S | 1 |
| Yoshino, T | 1 |
| Tanimoto, M | 1 |
| Persky, DO | 1 |
| Li, H | 1 |
| Rimsza, LM | 1 |
| Barr, PM | 1 |
| Popplewell, LL | 1 |
| Bane, CL | 1 |
| Von Gehr, A | 1 |
| LeBlanc, M | 1 |
| Fisher, RI | 2 |
| Smith, SM | 1 |
| Friedberg, JW | 1 |
| Abdullah, AS | 1 |
| Adel, AM | 1 |
| Hussein, RM | 1 |
| Abdullah, MA | 1 |
| Yousaf, A | 1 |
| Mudawi, D | 1 |
| Mohamed, SF | 1 |
| Nashwan, AJ | 1 |
| Soliman, D | 1 |
| Ibrahim, F | 1 |
| Yassin, MA | 1 |
| Kataoka, T | 1 |
| Sakurashita, H | 1 |
| Taogoshi, T | 1 |
| Nishigakiuchi, R | 1 |
| Murase, T | 1 |
| Izumitani, S | 1 |
| Saeki, Y | 1 |
| Matsuo, H | 1 |
| Guillet, S | 1 |
| Stokkermans, J | 1 |
| Vergier, B | 1 |
| Doutre, MS | 1 |
| Beylot-Barry, M | 1 |
| Park, S | 1 |
| Han, B | 1 |
| Cho, JW | 1 |
| Woo, SY | 1 |
| Kim, S | 1 |
| Wieringa, A | 1 |
| Boslooper, K | 1 |
| Hoogendoorn, M | 1 |
| Joosten, P | 1 |
| Beerden, T | 1 |
| Storm, H | 1 |
| Kibbelaar, RE | 1 |
| Veldhuis, GJ | 1 |
| van Kamp, H | 1 |
| van Rees, B | 1 |
| Kluin-Nelemans, HC | 1 |
| Veeger, NJ | 1 |
| van Roon, EN | 1 |
| Odejide, OO | 1 |
| Cronin, AM | 1 |
| Davidoff, AJ | 1 |
| LaCasce, AS | 1 |
| Abel, GA | 1 |
| Olszewski, AJ | 1 |
| Shafqat, H | 1 |
| Ali, S | 1 |
| Ganti, A | 1 |
| Liu, W | 1 |
| Luo, S | 1 |
| Sanfilippo, KM | 1 |
| Roop, R | 1 |
| Lynch, R | 1 |
| Riedell, P | 1 |
| O'Brian, K | 1 |
| Colditz, GA | 1 |
| Carson, KR | 1 |
| Lloret-Ruiz, C | 1 |
| Molés-Poveda, P | 1 |
| Barrado-Solís, N | 1 |
| Gimeno-Carpio, E | 1 |
| Wang, XJ | 1 |
| Tang, T | 1 |
| Farid, M | 1 |
| Quek, R | 1 |
| Tao, M | 1 |
| Lim, ST | 1 |
| Wee, HL | 1 |
| Chan, A | 1 |
| Maiti, A | 1 |
| Bhattacharya, S | 1 |
| Abali, H | 1 |
| Kiykim, AA | 1 |
| Engin, H | 1 |
| Güler, N | 1 |
| Morrison, VA | 1 |
| Weller, EA | 1 |
| Habermann, TM | 1 |
| Li, S | 1 |
| Cheson, BD | 1 |
| Peterson, BA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma[NCT05996185] | Phase 2 | 36 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma[NCT03586999] | Phase 1/Phase 2 | 18 participants (Actual) | Interventional | 2018-11-07 | Active, not recruiting | ||
| Phase III Trial of CHOP Versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients With Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin's Lymphoma[NCT00003150] | Phase 3 | 630 participants (Anticipated) | Interventional | 1997-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for prednisone and Febrile Neutropenia
| Article | Year |
|---|---|
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cyclin-Dependent Kinase 4; Docetaxel | 2022 |
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamid | 2020 |
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2017 |
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2017 |
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2017 |
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2017 |
A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cy | 2018 |
Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2017 |
21 other studies available for prednisone and Febrile Neutropenia
| Article | Year |
|---|---|
Risk of febrile neutropenia in very elderly patients aged ≥80 years receiving their first cycle of R-CHOP regimen: a nationwide real-world study in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Febrile Neutrop | 2022 |
Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin | 2022 |
Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Febrile Neutrop | 2022 |
Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections | 2020 |
Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocol | 2020 |
Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Communic | 2020 |
Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Febrile Neutropenia; | 2021 |
Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.
Topics: Aged, 80 and over; Aging; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemothera | 2017 |
Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2017 |
Hypercalcemia and acute pancreatitis in a male patient with acute promyelocytic leukemia and pulmonary tuberculosis.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Causality; Febrile Neut | 2018 |
[Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2019 |
[Acute neutrophilic dermatosis (pustular dermatitis) associated with aggressive transformed mycosis fungoides].
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Depsipept | 2013 |
Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthropometry; Antibodies, Monoclonal, Murine-Derived; A | 2014 |
Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort S | 2015 |
Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2015 |
Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Body M | 2014 |
Diffuse systemic large B-cell lymphoma with secondary skin involvement.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Tumor; | 2015 |
Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biosimilar P | 2016 |
A patient with cancer and nail pigmentation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Cyclophosphamide; | 2016 |
Is Granulocyte Colony-stimulating Factor Safe in the Treatment of Febrile Neutropenia in Lymphoma Patients with Renal Transplantation?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Febrile Neutropenia; | 2001 |